Beyfortus is the first long-acting monoclonal antibody approved by the FDA to prevent RSV-related lower respiratory tract disease in newborns and infants as well as children up to 24 months old, according to a Sept. 16 news release from the drug manufacturer.
Sanofi has started shipping doses to private healthcare providers and the CDC’s Vaccines for Children program, the release said.
Hospitals and clinics should plan to spend 11% to 13% more for prescription drugs in 2025 compared to last year,…
Boise, Idaho-based St. Luke’s Health System has erected automated medication lockers at supermarkets and other locations to increase access, ABC…
Health system pharmacists and physicians are monitoring a wave of expected new drug approvals between late 2024 and third quarter…
Comments are closed.
